Zenith presenting at 12th Annual BIOTECanada Investor Summit

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith presenting at 12th Annual BIOTECanada Investor Summit

posted on Feb 18, 2016 09:41PM

I confirmed with Sarah today that Zenith is one of ten companies selected to present at the upcoming 12th Annual BIOTECanada Investor Summit February 26-28, 2016 in Whistler, BC, Canada as listed on Zenith's events page.

The BIOTECanada Investor Summit presents a unique and timely opportunity for investors, commercial partners and pre-commercial companies to connect, network and explore investment/partnership opportunities within the Canadian biotech industry. Each year ten emerging companies in search of investment capital are provided the opportunity to present their company and therapy to the investors and pharma partners.